Naminidil

Naminidil
Clinical data
Other names	BMS-234303; BMS234303
Routes of; administration	Topical
Drug class	ATP-sensitive potassium channel opener; Vasodilator
Identifiers
	IUPAC name 1-cyano-3-(4-cyanophenyl)-2-[(2R)-3,3-dimethylbutan-2-yl]guanidine;
CAS Number	220641-11-2;
PubChem CID	158438;
ChemSpider	139379;
UNII	7K50VT05OD;
KEGG	D05114;
ChEMBL	ChEMBL2105160;
CompTox Dashboard (EPA)	DTXSID00176552 ;
Chemical and physical data
Formula	C15H19N5
Molar mass	269.352 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](C(C)(C)C)N=C(NC#N)NC1=CC=C(C=C1)C#N;
	InChI InChI=1S/C15H19N5/c1-11(15(2,3)4)19-14(18-10-17)20-13-7-5-12(9-16)6-8-13/h5-8,11H,1-4H3,(H2,18,19,20)/t11-/m1/s1; Key:PGYDRGZVXVVZQC-LLVKDONJSA-N;

Naminidil (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name BMS-234303) is an ATP-sensitive potassium channel opener with vasodilator activity which was under development as a topical medication for the treatment of androgenic alopecia (pattern hair loss) but was never marketed.^[2]^[3]^[1] The drug was under development by Bristol-Myers Squibb and reached phase 2 clinical trials by 2001.^[2] One of the phase 2 trials compared naminidil, minoxidil, and placebo for alopecia.^[1] However, no results of the study appear to have been made available.^[1] Development of naminidil was discontinued by 2008.^[2] In terms of chemical structure, naminidil is a guanidine derivative and is structurally distinct from minoxidil.^[2]^[4]

References

^ ^a ^b ^c ^d Poulos GA, Mirmirani P (February 2005). "Investigational medications in the treatment of alopecia". Expert Opinion on Investigational Drugs. 14 (2): 177–184. doi:10.1517/13543784.14.2.177. PMID 15757393.
^ ^a ^b ^c ^d "Naminidil". AdisInsight. 17 January 2008. Retrieved 23 July 2025.
^ "Delving into the Latest Updates on Naminidil with Synapse". Synapse. 20 July 2025. Retrieved 23 July 2025.
^ "Naminidil". PubChem. U.S. National Library of Medicine. Retrieved 24 July 2025.